A new study from Euroimmun, published in PLoS Neglected Tropical Diseases, demonstrates how customised testing for different dengue serological markers can improve diagnostic accuracy across different stages of infection. Diagnostic challenges Accurate diagnosis of dengue virus (DENV) infection is challenging due to its non-specific early symptoms and potential for rapid clinical deterioration. While RT-PCR is […]
Reliable and fast diagnostics of cervical cancer While HPV tests detect infections with HPV and thus allow drawing conclusions on the risk of developing cervical cancer, the GynTect® test can be used in a second step to clarify whether affected cells are actually already developing into cancer cells based on the detection of epigenetic markers.
Since end of 2020, different SARS-CoV-2 variants have appeared worldwide − alpha (B.1.1.7), beta (B.1.351), gamma (P.1/B.1.1.128) and delta (B1.617.2) − which are in part more contagious than the original virus type and are therefore spreading more quickly within populations. These variants reveal genetic changes (mutations) in the so-called receptor binding domain (RBD), which is
Six months after the start of the COVID-19 vaccination campaign in Germany, half of the population has received at least one vaccination dose. According to the Federal Ministry of Health, 37.9% of them have already been fully vaccinated (as of 02.07.2021). Currently there are four different COVID-19 vaccines available in Germany, which differ slightly in
Press Release Jena / Lübeck (GER) – Biotechnology company oncgnostics GmbH is announcing a collaboration with the international diagnostics group EUROIMMUN Medizinische Labordiagnostika AG. As part of the cooperation, EUROIMMUN will sell the cervical cancer test from oncgnostics GmbH, Gyn-Tect, in the European countries of Portugal, Italy, Turkey and Poland. The test is also expected
